<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737476</url>
  </required_header>
  <id_info>
    <org_study_id>sor010912ctil</org_study_id>
    <nct_id>NCT01737476</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy of the HLPFC Coil Deep Transcranial Magnetic Stimulation System in Treating Attention Deficit and Hyperactivity Disorder (ADHD) in Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the efficacy of trans-cranial magnetic stimulation in
      treating attention deficit disorder in adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Attention Deficit Disorder Patients</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>control-sham</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep TMS PFC Lt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep TMS PFC left</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEEP TMS PFC Rt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DEEP TMS PFC Rt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Superficial TMS PFC Lt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Superficial TMS PFC Lt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>superficial TMS PFC Rt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>superficial TMS PFC Rt</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation.  PFC</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>Deep TMS PFC Lt</arm_group_label>
    <arm_group_label>DEEP TMS PFC Rt</arm_group_label>
    <arm_group_label>Superficial TMS PFC Lt</arm_group_label>
    <arm_group_label>superficial TMS PFC Rt</arm_group_label>
    <other_name>Stimulator: Magstim rapid2. The Magstim Company Limited, Spring gardens, Whitland, Carmarthenshire, SA34 OHR, UK.</other_name>
    <other_name>Coil: HLPFC. Brainsway Ltd. 19 hartum St. Bynet Building, Har Hatzofim, Jerusalem, Israel.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years

          -  ADD/ADHD

        Exclusion Criteria:

          -  any DSM-IV psychiatric disorder except ADD/ADHD

          -  use of psychoactive medications

          -  Epilepsy

          -  brain injury
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hadar Shalev, MD</last_name>
    <phone>97286400353</phone>
    <email>shalev@bgu.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ben-Gurion University</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadar Shalev, MD</last_name>
      <phone>97286400353</phone>
      <email>shalev@bgu.ac.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 26, 2012</lastchanged_date>
  <firstreceived_date>September 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>age 18-65</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
